ストックスクリーナーアプリを入手
4.92
5.23%
-0.24
アフターアワーズ：
4.92
前日終値:
$5.16
開ける：
$5.16
24時間の取引高:
26,098
Relative Volume:
0.15
時価総額：
$9.62M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-9.94%
1か月 パフォーマンス:
-35.23%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.8901
$5.2361
1週間の範囲:
$4.8901
$5.43
52週間の値動き範囲:
$3.50
$8.86
Quantum Biopharma Ltd Stock (QNTM) Company Profile
QNTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| QNTM | 4.92 | 9.62M | 0 | 0 | 0 | 0.00 |
| ZTS | 176.44 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.44 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Quantum Biopharma Ltd (QNTM) 最新ニュース
Quantum BioPharma Ltd expected to post a loss of $3.90 a shareEarnings Preview - XM
Quantum BioPharma initiates phase 1 multiple sclerosis trial By Investing.com - Investing.com Canada
Quantum BioPharma sues CIBC and RBC seeking $700M in damages - MSN
Quantum BioPharma initiates phase 1 multiple sclerosis trial - Investing.com
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia - AccessWire
InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of DirectorsVideo Available on Investmentpitch.com - Marketscreener.com
Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma - Marketscreener.com
Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma - PR Newswire
Quantum BioPharma Ltd - Stockhouse Publishing
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH - Marketscreener.com
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spo - AccessWire
Quantum BioPharma posts link to lawsuit against CIBC World Markets, RBC Dominion - TipRanks
Quantum BioPharma alleges major market manipulation By Investing.com - Investing.com Australia
Quantum BioPharma sues over alleged stock spoofing - The Globe and Mail
Quantum BioPharma sues CIBC and RBC seeking $700M in damages | 2024-10-21 | Investing News - Stockhouse Publishing
Quantum BioPharma alleges major market manipulation - Investing.com
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing - Chronicle-Tribune
Quantum BioPharma (QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700M - StreetInsider.com
Quantum BioPharma Ltd. (NASDAQ: QNTM): Pioneering Alcohol Metabolism Support with Unbuzzd - openPR
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges - openPR
Quantum BioPharma Expands Market for Alcohol Metabolism Product Unbuzzd - Citybuzz
Celly Nu secures distribution for alcohol metabolism drink By Investing.com - Investing.com South Africa
Celly Nu secures distribution deal in the Caribbean By Investing.com - Investing.com South Africa
Celly Nu secures distribution deal in the Caribbean - Investing.com India
Celly Nu secures distribution for alcohol metabolism drink - Investing.com
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America - Newsfile
Quantum BioPharma Ltd. Pharma Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group Across Puerto Rico, the Caribbean, and Parts of Central and South America - WSIL TV
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America - AccessWire
Pre-market Movers: ALZN, VRAX, APDN, LQDA... - RTTNews
Quantum Biopharma Provides Corporate Update - GuruFocus.com
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US - Markets Insider
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US - Quantisnow
Investor.News Prepares for the ArcStone-Kingswood Growth Summit 2024 - InvestorNews Inc.
Quantum BioPharma Closes Private Placement Offering - Invezz
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know - MSN
Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation, Xorax Family Trust - Marketscreener.com
Quantum BioPharma to run multiple sclerosis progression study | 2024-09-09 | Investing News - Stockhouse Publishing
Quantum BioPharma partners for multiple sclerosis study - Investing.com
S&P 500 Materials [Sector] (SRMA) QuotePress Release - The Globe and Mail
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - Digital Journal
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease - PharmiWeb.com
Quantum Biopharma Ltd (QNTM) 財務データ
Quantum Biopharma Ltd (QNTM) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.70%
0.05%
大文字化:
|
ボリューム (24 時間):